Drug Profile
GLPG 2451
Alternative Names: ABBV 2451; GLPG2451Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis(Combination therapy) in Belgium (PO, Suspension)
- 28 May 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis(Combination therapy) in Bulgaria (PO, Suspension)
- 28 May 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis(Combination therapy) in Germany (PO, Suspension)